* PURPOSE1 HIV Prevention on Mon Jul 15 14:03:34 2024
- input data directory: .
- results directory: .
- transcript to: ./2024-07-11-hiv-prev-news.txt
Building summary data:
----------------------
* PURPOSE1 data as reported:
Arm N K Infp100py
1 lenacapavir 2134 0 0.00
2 Descovy 2136 39 2.02
3 Truvada 1068 16 1.69
* PURPOSE1 summary data for analysis:
Arm N K
1 lenacapavir 2134 0
2 PReP 3204 55
Naive efficacy/CL vs PReP controls::
------------------------------------
* Efficacy (%) over PReP, where 0% means comparable to PReP:
LCL Eff UCL
89.53 100.00 100.00
Frequentist tests of significance and strength:
-----------------------------------------------
* Significance test of proportion:
- Yates correction: TRUE
- Alternative: probability of infection same in both arms
2-sample test for equality of proportions with continuity correction
data: c(purpose1Summary[1, 3], purpose1Summary[2, 3]) out of c(purpose1Summary[1, 2], purpose1Summary[2, 2])
X-squared = 35.349, df = 1, p-value = 2.755e-09
alternative hypothesis: two.sided
95 percent confidence interval:
-0.02205396 -0.01227813
sample estimates:
prop 1 prop 2
0.00000000 0.01716604
* Computing Cohen's h for strength of effect
- Range of h is -pi to +pi
- anything with absolute value over 0.8 is a large effect.
- Result: |h| = 0.263
Plotting posterior Beta distributions for probability of infection:
-------------------------------------------------------------------
* Doing Baysian posterior Beta distribution analysis.
* Posterior quantiles:
0.025 0.5 0.975
lenacapavir 0.00001 0.00032 0.00173
PReP 0.01322 0.01737 0.02228
* Bayesian Beta posterior plot to ./2024-07-11-hiv-prev-news.png.
* Frequentist heuristic for lenacapavir infection CL
- Rule of 3: [0.0000000, 0.0014058]
- Bayes: [0.0000119, 0.0017263].
* PURPOSE1 HIV Prevention completed Mon Jul 15 14:03:34 2024 (0.0 sec elapsed).